The expression and biological functions of sphingosine-1-phosphate receptor 4 in oral squamous cell carcinoma

doi:10.19438/j.cjoms.2024.01.002

Abstract

Abstract: PURPOSE: To explore the expression and biological functions of sphingosine-1-phosphate receptor 4 (S1PR4) in oral squamous cell carcinoma (OSCC). METHODS: The expression of S1PR4 in OSCC tissue samples and cell lines (WSU-HN4, WSU-HN6, CAL27, WSU-HN30) was analyzed by RT-qPCR, Western blot and IHC. The activity of S1PR4 was inhibited by S1PR4 antagonist(CYM50358), and the effect of CYM50358 on proliferation of OSCC cells was detected by CCK-8 and clonal formation assay. The effect of CYM500358 on apoptosis of OSCC cells was evaluated by flow cytometry. SPSS 23.0 software package was used for statistical analysis. RESULTS: The transcription and expression of S1PR4 were up-regulated in OSCC. The activity of proliferation and clonality were decreased(P<0.05), while the percentage of apoptotic cells was increased in CYM50358-treated OSCC cells(P<0.05). CONCLUSIONS: The expression of S1PR4 is up-regulated in OSCC. S1PR4 antagonist can significantly reduce viability and promote apoptosis of OSCC cells, and may be a potential indicator for treatment of OSCC.

Key words: Oral squamous cell carcinoma, OSCC, Sphingosine-1-phosphate receptor 4(S1PR4), Biological function, Apoptosis

CLC Number:

R739.8

ZHOU Xin-xia, LIU Jing-hao, GAN Gui-fang, CHEN Fu-xiang. The expression and biological functions of sphingosine-1-phosphate receptor 4 in oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(1): 10-15.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249.
[2] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92-141.
[3] Blatt S, Krüger M, Ziebart T, et al. Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: a review of the literature[J]. J Craniomaxillofac Surg, 2017, 45(5): 722-730.
[4] Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma-an update: oral & oropharyngeal cancer update[J]. CA Cancer J Clin, 2015, 65(5): 401-421.
[5] Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy[J]. Nat Rev Cancer, 2018, 18(1):33-50.
[6] Roi A, Roi CI, Negru?iu ML, et al. The challenges of OSCC diagnosis: salivary cytokines as potential biomarkers[J]. J Clin Med, 2020, 9(9): 2866.
[7] Shrestha AD, Vedsted P, Kallestrup P, et al. Prevalence and incidence of oral cancer in low- and middle-income countries: a scoping review[J]. Eur J Cancer Care (Engl), 2020,29(2): e13207.
[8] Du Y, Peyser ND, Grandis JR. Integration of molecular targeted therapy with radiation in head and neck cancer[J]. Pharmacol Ther, 2014, 142(1): 88-98.
[9] Chun J, Hla T, Lynch KR, et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature[J]. Pharmacol Rev, 2010,62(4):579-587.
[10] Liu S, Ni C, Zhang D, et al. S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer[J]. Cell Death Dis, 2019, 10(3): 200-215.
[11] Anu B, Namitha NN, Harikumar KB. S1PR1 signaling in cancer: a current perspective[J]. Adv Protein Chem Struct Biol, 2021, 125: 259-274.
[12] Shen Y, Zhao S, Wang S, et al. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma[J]. EBioMedicine, 2019, 40: 210-223.
[13] Wang W, Hind T, Lam BWS, et al. Sphingosine 1-phosphate signaling induces SNAI2 expression to promote cell invasion in breast cancer cells[J]. FASEB J, 2019, 33(6): 7180-7191.
[14] Zhao J, Liu J, Lee JF, et al. TGF-β/SMAD3 pathway stimulates sphingosine-1 phosphate receptor 3 expression: implication of sphingosine-1 phosphate receptor 3 in lung adenocarcinoma progression[J]. J Biol Chem, 2016,291(53): 27343-27353.
[15] Sarkar J, Aoki H, Wu R, et al. Conjugated bile acids accelerate progression of pancreatic cancer metastasis via S1PR2 signaling in cholestasis[J]. Ann Surg Oncol, 2023, 30(3): 1630-1641.
[16] Yamashita H, Kitayama J, Shida D, et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation[J]. J Surg Res, 2006, 130(1): 80-87.
[17] Petti L, Rizzo G, Rubbino F, et al. Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer[J]. J Exp Clin Cancer Res, 2020, 39(1): 253-267.
[18] Ohotski J, Rosen H, Bittman R,et al. Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: the role of sphingosine 1-phosphate receptor-4[J]. Cell Signal, 2014, 26(5): 1040-1047.
[19] Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy[J]. Science, 2019,366(6463): eaar5551.
[20] Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis[J]. Nat Rev Drug Discov, 2010, 9(11): 883-897.
[21] Gaber T.Siponimod for active secondary progressive multiple sclerosis[J]. Prog Neurol Psychiatry, 2021, 25(2): 4-5.
[22] Blanco R, Martínez-Navarrete G, Valiente-Soriano FJ, et al. The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss[J]. Exp Eye Res, 2017, 164: 37-45.
[23] Weske S, Vaidya M, Von Wnuck Lipinski K, et al. Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice[J]. Bone, 2019, 125(1): 1-7.
[24] Li MH, Swenson R, Harel M, et al. Antitumor activity of a novel sphingosine-1-phosphate 2 antagonist, AB1, in neuroblastoma[J]. J Pharmacol Exp Ther, 2015, 354(3): 261-268.
[25] Onuma T, Tanabe K, Kito Y, et al. Sphingosine 1-phosphate (S1P) suppresses the collagen-induced activation of human platelets via S1P4 receptor[J]. Thrombosis Res, 2017, 156(1): 91-100.
[26] Salomone S, Waeber C. Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects[J]. Front Pharmacol, 2011, 2(1): 9-16.
[27] Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate[J]. Br J Pharmacol, 2012, 167(5): 1035-1047.